The latest cut of data from a trial of Amgen’s closely watched Kras inhibitor AMG 510 contains more encouraging signals in lung cancer, though some of the loftiest hopes…
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
The Japanese company is to hand across $3bn to Roivant for various subsidiaries that hold an eclectic portfolio of assets.
Deal is the fifth largest robotics surgery purchase ever, and the second big move from Stryker.
Among small-molecule approaches Europe’s premier oncology conference gives star billing to three Parp inhibitors in ovarian cancer.
Tocagen’s Toca-5 trial has survived two interim reviews, and faces final readout by the end of this year.
A win with a tenapanor combo could bode well for the project’s monotherapy chances.
Carmat says its artificial heart is the best such device in existence. But time is short, and so is money.
A collection of all of Vantage's coverage from the 2019 European Society of Cardiology meeting.
Having succeeded with cystic fibrosis Vertex is now chasing a cure for type 1 diabetes.
Concert believes that high-dose data with CTP-543 will help it challenge Pfizer, but patent questions still loom large.
Amarin is plugging a change in ESC guidelines to include Vascepa, but with the product’s regulatory fate undecided how much difference will this make to sales?
With decent efficacy and clean safety in the Orion-11 trial, questions now turn to pricing and whether The Medicines Company will be taken out.
An increased risk of bleeding outweighs Brilinta’s benefits in a primary prevention population, but there might be a way forward in a patient subgroup.
Before today’s trial readout no one was sure how remote ischaemic conditioning worked; now the investigators are pretty certain that it doesn’t.
With a narrow primary endpoint miss and a 15% decrease in hospitalisations, Novartis is adamant that Entresto can get approved in HFpEF.
With strong data in hand Astrazeneca now needs to get cardiologists on board, and stay ahead of Lilly and Boehringer.
Lilly is awaiting the first set of pivotal data with the cytokine agent it bought from Armo last year, while Biohaven heads for migraine catalysts.
The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.